NTRK1 and glioblastoma: Additionally, while small molecule inhibitors often inhibit multiple types of tyrosine kinase, in general they are insufficient to block all receptor signaling, and as a result GBM may simply respond by upregulating or activating these same tyrosine kinase receptors (85).